Portmanteau inhibitor

A portmanteau inhibitor is a drug that is a combination of two drug molecules, each of which is itself a type of inhibitor. The term was coined in 2007 by University of Minnesota researchers who designed and synthesized a combination HIV reverse transcriptase inhibitor and an integrase inhibitor,[1][2][3] and was further used in 2011 by a team of researchers combining an integrase inhibitor with a CCR5 entry inhibitor.[4]

Footnotes
  1. "U of M researchers announce advance in treatment of HIV". 25 July 2007. Retrieved 25 July 2007.
  2. "Researchers Discover New Method To Combat HIV". 25 July 2007. Retrieved 25 July 2007.
  3. Zhengqiang Wang; Eric M. Bennett; Daniel J. Wilson; Christine Salomon; Robert Vince (2007). "Rationally Designed Dual Inhibitors of HIV Reverse Transcriptase and Integrase". Journal of Medicinal Chemistry. 50 (15): 3416–3419. CiteSeerX 10.1.1.535.8472. doi:10.1021/jm070512p. PMID 17608468.
  4. Bodiwala, H. S.; Sabde, S.; Gupta, P.; Mukherjee, R.; Kumar, R.; Garg, P.; Bhutani, K. K.; Mitra, D.; Singh, I. P. (2011). "Design and synthesis of caffeoyl-anilides as portmanteau inhibitors of HIV-1 integrase and CCR5". Bioorganic & Medicinal Chemistry. 19 (3): 1256–63. doi:10.1016/j.bmc.2010.12.031. PMID 21227704.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.